Quest Diagnostics Incorporated (LON:0KSX)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 13.87B |
| Revenue (ttm) | 7.86B |
| Net Income (ttm) | 690.40M |
| Shares Out | n/a |
| EPS (ttm) | 6.12 |
| PE Ratio | 20.09 |
| Forward PE | 16.41 |
| Dividend | 2.40 (1.43%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 113 |
| Average Volume | 70 |
| Open | 168.32 |
| Previous Close | 167.76 |
| Day's Range | 165.35 - 168.41 |
| 52-Week Range | 138.36 - 182.23 |
| Beta | 0.49 |
| RSI | 37.49 |
| Earnings Date | Jul 22, 2025 |
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,... [Read more]
Financial Performance
In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $866.00 million, an increase of 1.88%.
Financial numbers in USD Financial StatementsNews
Woman (54) with terminal cervical cancer settles case over smear tests
Settlement with HSE and Quest Diagnostics Incorporated reached without admission of liability
Quest Diagnostics Releases 2024 Corporate Responsibility Report
SECAUCUS, N.J. , June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.
Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025
SECAUCUS, N.J. , June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial resu...
Quest Diagnostics Stock Trades Near A Buy Zone; Capture Profits With This Long Call Butterfly In Options Trading
Quest Diagnostics stock is hovering in and around a buy zone. To limit risk, consider using a long call butterfly setup in options.
Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
SECAUCUS, N.J. , June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD And...
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
Quest Diagnostics (NYSE: DGX) has outperformed the market over the past 5 years by 276.89% on an annualized basis producing an average annual return of 290.74%. Currently, Quest Diagnostics has a mar...
More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Quest Diagnostics (NYSE: DGX) has outperformed the market over the past 5 years by 305.46% on an annualized basis producing an average annual return of 320.73%. Currently, Quest Diagnostics has a mar...
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J. , May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak...
Quest Diagnostics declares $0.80 dividend
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend...
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds
More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors th...
Quest Diagnostics: A Leader But Waiting For Better Price
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
Quest Diagnostics (NYSE: DGX) has outperformed the market over the past 5 years by 290.7% on an annualized basis producing an average annual return of 304.55%. Currently, Quest Diagnostics has a mark...
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Quest Diagnostics Incorporated (NYSE: DGX) posted better-than-expected first-quarter earnings on Tuesday . Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst cons...
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Quest Diagnostics Inc (NYSE: DGX) reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion . The diagnostic test provider repor...
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion.
Quest Diagnostics Incorporated (DGX) Q1 2025 Earnings Call Transcript
Quest Diagnostics up 8% following earnings beats, EPS guidance raise
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday. Shares of Quest Diagnostics Incorporated (NYSE: DGX) rose sharply during Tuesday's session following better-tha...
Quest Diagnostics Looks Like A 'Safe Haven' After First-Quarter Beat
Quest Diagnostics stock remains a "safe haven," an analyst said Tuesday after the company topped first-quarter expectations.
Quest beats quarterly profit estimates on strong demand for diagnostic tests
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.